RxSight (RXST) investor relations material

First quarter performance and market dynamics

• LAL volumes in Q1 2026 were in line with expectations, with no significant weather or unique issues impacting results.

• Premium IOL market remains a focus for clinicians as they seek to offset reductions in reimbursed business.

• Despite lower overall cataract volumes, premium IOL penetration is increasing, driven by maintained or growing premium case numbers.

Competitive landscape and guidance

• New lens introductions in late 2024 and 2025 led to temporary trialing and sampling, but fixed IOLs are not seen as differentiated versus LAL.

• Guidance for 2026 incorporates a range of competitive scenarios, with the midpoint assuming less acute headwinds than in 2025.

• Ongoing monitoring of competition and consumer trends is emphasized, especially given macroeconomic uncertainties.

Commercial initiatives and growth strategy

• Commercial initiatives since mid-2025 focus on driving same-store sales and providing clinicians with tools and data to improve outcomes.

• Programs are being refined to scale the most impactful initiatives, aiming to boost LAL adoption.

• Share gains are expected over the long term, with a current 10% volume share and 15% dollar share in the U.S. premium IOL market.

• Growth is attributed to attracting patients from monofocal and toric IOLs, expanding the premium segment.